HPC Biosciences [HPBL] vs Uflex Limited [UFLEX] Detailed Stock Comparison

HPC Biosciences Ltd.

BSE
Loading...

Uflex Limited

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: HPC Biosciences Ltd. wins in 11 metrics, Uflex Limited wins in 8 metrics, with 0 ties. HPC Biosciences Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric HPC Biosciences Ltd. Uflex Limited Better
P/E Ratio (TTM) 9.38 9.74 HPC Biosciences Ltd.
Price-to-Book Ratio 2.55 0.36 Uflex Limited
Debt-to-Equity Ratio 219.28 120.69 Uflex Limited
PEG Ratio 0.03 -0.13 HPC Biosciences Ltd.
EV/EBITDA 8.34 6.33 Uflex Limited
Profit Margin (TTM) 3.53% 1.94% HPC Biosciences Ltd.
Operating Margin (TTM) 14.19% 6.70% HPC Biosciences Ltd.
EBITDA Margin (TTM) 14.19% 6.70% HPC Biosciences Ltd.
Return on Equity 12.16% 1.92% HPC Biosciences Ltd.
Return on Assets (TTM) 3.38% 0.73% HPC Biosciences Ltd.
Free Cash Flow (TTM) $-189.52M $-5.97B HPC Biosciences Ltd.
Dividend Yield N/A 0.69% N/A
1-Year Return 42.25% -30.97% HPC Biosciences Ltd.
Price-to-Sales Ratio (TTM) 0.38 0.19 Uflex Limited
Enterprise Value $4.40B $109.88B Uflex Limited
EV/Revenue Ratio 0.78 0.74 Uflex Limited
Gross Profit Margin (TTM) 48.80% 40.87% HPC Biosciences Ltd.
Revenue per Share (TTM) $434 $2,067 Uflex Limited
Earnings per Share (Diluted) $21.73 $40.12 Uflex Limited
Beta (Stock Volatility) -0.01 0.48 HPC Biosciences Ltd.

HPC Biosciences Ltd. vs Uflex Limited Stock Performance Analysis

Loading Price Chart...

HPBL
UFLEX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
HPC Biosciences Ltd.-0.80%-8.93%-12.73%34.39%24.06%36.37%
Uflex Limited-1.49%7.21%-1.65%-2.31%-7.96%-11.85%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
HPC Biosciences Ltd.42.25%-0.26%-59.52%-59.52%-59.52%-59.52%
Uflex Limited-30.97%3.14%-4.17%106.86%113.42%542.84%

Performance & Financial Health Analysis: HPC Biosciences Ltd. vs Uflex Limited

MetricHPBLUFLEX
Market Information
Market Cap i₹2.17B₹28.21B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i9,11655,033
90 Day Avg. Volume i5,70885,183
Last Close₹248.00₹439.45
52 Week Range₹140.10 - ₹284.45₹330.00 - ₹648.00
% from 52W High-12.81%-32.18%
All-Time High₹704.50 (Jan 17, 2022)₹859.80 (Aug 19, 2024)
% from All-Time High-64.80%-48.89%
Growth Metrics
Quarterly Revenue Growth0.02%-0.04%
Quarterly Earnings Growth3.27%-0.74%
Financial Health
Profit Margin (TTM) i0.04%0.02%
Operating Margin (TTM) i0.14%0.07%
Return on Equity (TTM) i0.12%0.02%
Debt to Equity (MRQ) i219.28120.69
Cash & Liquidity
Book Value per Share (MRQ)₹79.86₹1,071.11
Cash per Share (MRQ)₹1.91₹160.41
Operating Cash Flow (TTM) i₹-217,642,000₹3.31B
Levered Free Cash Flow (TTM) i₹96.26M₹1.42B
Dividends
Last 12-Month Dividend Yield iN/A0.69%
Last 12-Month Dividend iN/A₹4.00

Valuation & Enterprise Metrics Analysis: HPC Biosciences Ltd. vs Uflex Limited

MetricHPBL (Apr 24, 2026)UFLEX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i9.389.74
Forward P/E iN/A6.92
PEG Ratio i0.03-0.13
Price to Sales (TTM) i0.380.19
Price to Book (MRQ) i2.550.36
Market Capitalization
Market Capitalization i₹2.17B₹28.21B
Enterprise Value i₹4.40B₹109.88B
Enterprise Value Metrics
Enterprise to Revenue i0.780.74
Enterprise to EBITDA i8.346.33
Risk & Other Metrics
Beta i-0.010.48
Book Value per Share (MRQ) i₹79.86₹1,071.11

Financial Statements Comparison: HPC Biosciences Ltd. vs Uflex Limited

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHPBL (2025)UFLEX (2025)
Revenue/Sales i4.61B148.45B
Cost of Goods Sold i3.93B107.17B
COGS % of Revenue i85.2%72.2%
Gross Profit i680.37M41.28B
Gross Margin i14.8%27.8%
Research & Development iN/AN/A
Operating Income (EBIT) i300.06M10.77B
Operating Margin i6.5%7.3%
EBITDA i386.57M17.96B
EBITDA Margin i8.4%12.1%
Pre-Tax Income i195.76M2.48B
Pre-Tax Income % of Revenue i4.2%1.7%
Income Tax i46.49M1.06B
Income Tax % of Revenue i1.0%0.7%
Net Income (Profit) i133.31M1.42B
Profit Margin i2.9%1.0%

Balance Sheet & Liquidity Metrics

MetricHPBL (2025)UFLEX (2025)
Cash & Equivalents i7.79M11.25B
Total Current Assets i1.80B84.58B
Total Current Assets % of Revenue i39.0%57.0%
Total Current Liabilities i1.70B64.61B
Total Current Liabilities % of Revenue i36.9%43.5%
Long-Term Debt i324.35M50.90B
Long-Term Debt % of Revenue i7.0%34.3%
Total Shareholders Equity i791.64M73.96B
Retained Earnings i-337.75M51.01B
Retained Earnings % of Revenue i-7.3%34.4%
Property, Plant & Equipment i80.41M7.42B

Cash Flow Statement Comparison

MetricHPBL (2025)UFLEX (2025)
Operating Cash Flow i-217.64M3.31B
Operating Cash Flow % of Revenue i-4.7%2.2%
Capital Expenditures i2.99M-17.26B
Free Cash Flow i-189.52M-5.97B
FCF Margin i-4.1%-4.0%
Debt Repayment i-151.53MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricHPBLUFLEX
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i10.67M72.21M
Float Shares i1.06M11.09M
% Held by Insiders i92.61%82.42%
% Held by Institutions i0.00%1.43%
% Held by Public i7.39%16.15%

Dividend Analysis & Yield Comparison: HPC Biosciences Ltd. vs Uflex Limited

MetricHPBLUFLEX
Last 12-Month Dividend iN/A₹4.00
Last 12-Month Dividend Yield iN/A0.69%
3-Year Avg Annual Dividend iN/A₹4.33
3-Year Avg Dividend Yield iN/A0.51%
3-Year Total Dividends iN/A₹13.00
Ex-Dividend DateN/AAug 01, 2025